Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 5, 2008, Pages 647-653

  Zhang, Qingyuan ^a   Kang, Xinmei ^a   Yang, Baofeng ^a   Wang, Jingxuan ^a   Yang, Fang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Breast neoplasm; Capecitabine; Chemotherapy; Ginsenoside Rg3

Indexed keywords

CAPECITABINE; GINSENOSIDE RG 3;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GINSENOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55849083086     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0532     Document Type: Article

References (21)

1. Briest S, Stearns V. Chemotherapeutic strategies for advanced breast cancer. Oncology (Williston Park) 2007;21:1325.
2. Ishikawa T, Utoh M, Sawada N, et al. Tumor-selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998;55:1091.
3. Dent S, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: A systematic review. Breast Cancer Res Treat 2008;108:319.
4. Munoz R, Shaked Y, Bertolini F, et al. Antiangiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005;14:466.
5. Yue PY, Wong DY, Wu PK, et al. The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem Pharmacol 2006;72:437.
6. Mochizuki M, Yoo YC, Matsuzawa K, et al. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)-, and 20(S)-ginsenoside-Rg3, of red ginseng. Biol Pharm Bull 1995;18:1197.
7. Kwon HY, Kim EH, Kim SW, et al. Selective toxicity of ginsenoside Rg3 on multidrug resistant cells by membrane fluidity modulation. Arch Pharm Res 2008;31:171.
8. Baguley BC, Holdaway KM, Thomsen LL, et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 1991;27:482.
9. Bocci G, Nicolaou KC, Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938.
10. Drevs J, Fakler J, Eisele S, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004;24:1759.
11. Miller KD, Sweeney CJ, Sledge GW. Refining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195.
12. Tabruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 2007;355:1.
13. Shimizu K, Asai T, Oku N. Antineovascular therapy, a novel antiangiogenic approach. Exp Opin Ther Targ 2005;9:63.
14. Kamat AA, Kim TJ, Landen CN, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281.
15. Christine MW, Pharm D, Celeste L, et al. Capecitabine: A review. Clin Ther 2005;27:23.
16. Sezgin C, Kurt E, Evrensel T, et al. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. South Med J 2007;100:27.
17. Wang CZ, Aung HH, Ni M, et al. Red American ginseng: Ginsenoside constituents and antiproliferative activities of heat-processed Panax quinquefolius roots. Planta Med 2007;73:669.
18. O'Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targ 2006;6:365.
19. Laquente B, Vinals F, Germa JR. Metronomic chemotherapy: An antiangiogenic scheduling. Clin Transl Oncol 2007;9:93.
20. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with serum vascular endothelial growth factor levels. Ann Oncol 2002;13:73.
21. Kim SW, Kwon HY, Chi DW, et al. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem Pharmacol 2003;65:75.